Press Release

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its third quarter 2017 financial results after the close of market on Monday, November 6, 2017. Following the announcement, Veracyte will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The call may be accessed as follows:

The webcast replay will be available on the company's website approximately two hours following completion of the call and archived on the company's website.

About Veracyte

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005596/en/

Veracyte, Inc.
Media:
Tracy Morris
650-380-4413
tracy.morris@veracyte.com
or
Investors:
Jackie Cossmon
650-243-6371
jackie@veracyte.com

Source: Veracyte, Inc.

News Provided by Acquire Media